Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:51:55 2026-06-17 am EDT			5-day change	1st Jan Change
126.59 ^USD	-0.50%		+4.69%	+3.61%

Jun. 16	Gilead Sciences Insider Sold Shares Worth $376,200, According to a Recent SEC Filing	MT
Jun. 16	Warsh Takes the Stage

Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.

Published on 05/07/2026 at 05:12 pm EDT

S&P Capital IQ

GILEAD SCIENCES, INC.

-0.50%

From January 1, 2026 to March 31, 2026, the company has repurchased 3,067,000 shares, representing 0.25% for $420.26 million. With this, the company has completed the repurchase of 48,876,844 shares, representing 3.92% for $4,571.75 million under the buyback announced on February 25, 2020.

Latest news about Gilead Sciences, Inc.

Jun. 16	Gilead Sciences Insider Sold Shares Worth $376,200, According to a Recent SEC Filing	MT
Jun. 16	Warsh Takes the Stage
Jun. 16	The market rediscovers its cloak of invincibility
Jun. 15	Gilead Sciences Says US FDA Accepts Supplemental NDA for Yeztugo for HIV Prevention	MT
Jun. 15	Gilead Sciences Receives Fda Acceptance for Supplemental New Drug Application for Once-Weekly Oral Yeztugo for Hiv Prevention	CI
Jun. 15	Global drugmakers invest billions to boost US presence	RE
Jun. 10	Lakefront Announces Share Buyback Program
Jun. 09	Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program	MT
Jun. 09	Gilead Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
Jun. 09	What Bundibugyo Ebola vaccines and treatments are under development	RE
Jun. 09	Wall Street Rises, Risks Remain
Jun. 08	Gilead, Merck HIV Combination Meets Primary Endpoint in Two Phase 3 Trials	MT
Jun. 08	Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials	DJ
Jun. 08	Merck, Gilead Discontinue Phase 3 Trial of Trodelvy, Keytruda to Treat Lung Cancer	MT
Jun. 08	Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment	CI

Chart Gilead Sciences, Inc.

Duration

Period

GILD: Dynamic Chart

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).

Employees

17,000

Sector

Pharmaceuticals

More about the company